tucatinib,trastuzumab
seagen
 with about 5.5% of crc pts developing her2 amplification post egfri treatment..
opens up new possibilities for patient care.
volunteer #CRCSM librarian
#BRAF & #NRAS FB grps
Stage 4 CRC Support & Colon Cancer Stars
trials Stage 2/3 pts
https://t.co/48vU5493pH